Marathon Capital Management Acquires 18,425 Shares of Quanterix Co. (NASDAQ:QTRX)

Marathon Capital Management raised its holdings in Quanterix Co. (NASDAQ:QTRX) by 15.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 137,560 shares of the company’s stock after buying an additional 18,425 shares during the quarter. Marathon Capital Management’s holdings in Quanterix were worth $1,817,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Lord Abbett & CO. LLC increased its holdings in Quanterix by 22.9% in the 1st quarter. Lord Abbett & CO. LLC now owns 1,757,153 shares of the company’s stock valued at $41,398,000 after buying an additional 326,876 shares during the period. Superstring Capital Management LP bought a new stake in shares of Quanterix in the 4th quarter worth about $1,962,000. Williams Jones Wealth Management LLC. acquired a new stake in shares of Quanterix during the 1st quarter worth about $1,327,000. Easterly Investment Partners LLC lifted its holdings in Quanterix by 551.1% during the 1st quarter. Easterly Investment Partners LLC now owns 78,734 shares of the company’s stock valued at $1,855,000 after purchasing an additional 66,642 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Quanterix by 15.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 974,111 shares of the company’s stock valued at $26,635,000 after buying an additional 131,195 shares in the last quarter. Institutional investors own 86.48% of the company’s stock.

Insider Transactions at Quanterix

In related news, Director David R. Walt bought 47,000 shares of Quanterix stock in a transaction dated Tuesday, August 20th. The shares were bought at an average cost of $13.29 per share, for a total transaction of $624,630.00. Following the completion of the transaction, the director now owns 1,487,342 shares of the company’s stock, valued at $19,766,775.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.90% of the stock is owned by company insiders.

Quanterix Trading Down 1.3 %

Shares of QTRX stock opened at $12.98 on Friday. Quanterix Co. has a 1 year low of $10.50 and a 1 year high of $29.70. The firm’s 50 day moving average is $13.26 and its 200-day moving average is $16.05. The firm has a market capitalization of $496.74 million, a price-to-earnings ratio of -13.52 and a beta of 1.36.

Quanterix (NASDAQ:QTRX) last announced its earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Quanterix had a negative return on equity of 11.52% and a negative net margin of 30.71%. The company had revenue of $34.38 million for the quarter, compared to analyst estimates of $34.19 million. During the same quarter in the previous year, the company posted ($0.16) earnings per share. On average, equities research analysts forecast that Quanterix Co. will post -0.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

QTRX has been the topic of a number of recent analyst reports. Scotiabank reduced their price target on shares of Quanterix from $32.00 to $28.00 and set a “sector outperform” rating on the stock in a research report on Monday, August 12th. TD Cowen reduced their price target on shares of Quanterix from $17.00 to $15.00 and set a “hold” rating on the stock in a research report on Friday, August 9th. Finally, The Goldman Sachs Group reduced their price target on shares of Quanterix from $35.00 to $24.00 and set a “buy” rating on the stock in a research report on Tuesday, July 9th.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.